Home › Endometrial Cancer › Minnesota
Endometrial Cancer clinical trials in Minnesota
39 studies for Endometrial Cancer are looking for participants at sites in Minnesota.
Cities in Minnesota
- Rochester20 studies
- Minneapolis18 studies
- Saint Paul6 studies
- Duluth5 studies
- Brooklyn Park5 studies
- Bloomington4 studies
- Plymouth4 studies
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Sanford Joe Lueken Cancer Center, Bemidji
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- and 12 more
RecruitingPhase 2
All ages · All sexes · Updated Oct 2, 2026 · NCT05564377Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- Essentia Health Saint Joseph's Medical Center, Brainerd
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- and 11 more
RecruitingPhase 3
Ages 18 and older · Women · Updated Oct 2, 2026 · NCT07198074A Phase 1 Study of the Safety and Tolerability of CTX-10726
- Mayo Clinic Rochester, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07419841A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Health Partners Frauenshuh Cancer Center, Saint Louis Park
- Health Partners Cancer Center at Regions Hospital, Saint Paul
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06172478Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- Mayo Clinic, Rochester
RecruitingObservational study
Ages 18 and older · Women · Updated Sep 29, 2026 · NCT05051722Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- and 11 more
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 28, 2026 · NCT05112601Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- Mayo Clinic - Rochester, Rochester
RecruitingPhase 1/2
Ages 18 and older · Women · Updated Sep 25, 2026 · NCT03564340Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
- Mercy Hospital, Coon Rapids
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 24, 2026 · NCT05640999A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Minnesota Oncology Hematology, PA ( Site 8003), Minneapolis
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 17, 2026 · NCT06952504A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Mayo Rochester, Rochester
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07109726ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Mayo Clinic (Rochester), Rochester
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT05059444Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
- USOR - Minnesota Oncology-Coon Rapids Clinic, Coon Rapids
- USOR - Minnesota Oncology/ Coon Rapids Clinic, Coon Rapids
- USOR - Minnesota Oncology - Edina Clinic, Edina
- and 7 more
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 9, 2026 · NCT07166094DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Research Site, Marshall
- Research Site, Minneapolis
- Research Site, Rochester
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 3, 2026 · NCT06989112FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
- University of Minnesota Masonic Cancer Center, Minneapolis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT07216105Flyte Device for Improving Urinary Incontinence Among Endometrial and Cervical Cancer Survivors Who Have Undergone Radiation Therapy
- Mayo Clinic in Rochester, Rochester
Recruiting
Ages 21 and older · Women · Updated Aug 31, 2026 · NCT07662824Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- University of Minnesota, Minneapolis
RecruitingPhase 1
Ages 15 and older · All sexes · Updated Aug 25, 2026 · NCT06276491Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- University of Minnesota/Masonic Cancer Center, Minneapolis
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer
- Mayo Clinic in Rochester, Rochester
Recruiting
Ages 18 and older · Women · Updated Aug 19, 2026 · NCT04567771A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Minneapolis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07182149FOG-001 in Locally Advanced or Metastatic Solid Tumors
- M Health Fairview University of Minnesota Medical Center, Minneapolis
- Mayo Clinic, Rochester
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05919264A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- M Health Fairview University of Minnesota Medical Center, Minneapolis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT06330064Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Minnesota Oncology Hematology, Maplewood
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT05579366A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Minnesota Oncology Hematology, Maple Grove
- Mayo Clinic (Minnesota), Rochester
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT04657068Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Minneapolis
RecruitingPhase 3
Ages 18 and older · Women · Updated Jul 29, 2026 · NCT07044336Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- 518, Minneapolis
RecruitingPhase 2
Ages 18 and older · Women · Updated Jul 16, 2026 · NCT06906341Acceptability of Testing DNA Markers in Vaginal Fluid for the Detection of Endometrial Cancer
- Mayo Clinic in Rochester, Rochester
RecruitingObservational studyHealthy volunteers welcome
Ages 45 and older · Women · Updated Jul 9, 2026 · NCT07527143Integrated Cancer Repository for Cancer Research
- Riverwood Healthcare Center, Aitkin
- Essentia Health-St. Joseph's Medical Center, Brainerd
- Essentia Health - Duluth Clinic, Duluth
- and 2 more
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Mayo Clinic - Rochester, Rochester
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT05377996Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding
- Mayo Clinic in Rochester, Rochester
RecruitingObservational study
Ages 55 and older · Women · Updated Jun 10, 2026 · NCT06365905Molecular and ctDNA Characterization of High-Risk Endometrial Cancer
- Mayo Clinic in Rochester, Rochester
RecruitingObservational study
Ages 18 and older · Women · Updated Apr 13, 2026 · NCT07062016Avera Cancer Sequencing and Analytics Protocol (ASAP)
- Avera Cancer Institute - Marshall, Marshall
RecruitingObservational study
Ages 18 and older · All sexes · Updated Mar 27, 2026 · NCT05142033A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- Mayo Clinic, Rochester
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Mar 27, 2026 · NCT06395519Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
- Mayo Clinic in Rochester, Rochester
RecruitingObservational study
Ages 18 and older · All sexes · Updated Mar 12, 2026 · NCT06349642Screening and Staging of Benign vs Malignant Pelvic Abnormalities
- Mayo Clinic in Rochester, Rochester
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Feb 17, 2026 · NCT07407959First in Human Study of TORL-1-23 in Participants With Advanced Cancer
- University of Minnesota, Minneapolis
- Mayo Clinic in Rochester, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT05103683cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Allina Health Cancer Institute, Minneapolis
- Mayo Clinic, Rochester
RecruitingObservational studyHealthy volunteers welcome
Ages 40 and older · All sexes · Updated Jan 20, 2026 · NCT05366881Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
- Minnesota Oncology Hematology, P.A., Maple Grove
RecruitingPhase 2
Ages 18 and older · Women · Updated Dec 24, 2025 · NCT06463028SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Duluth
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
- Minnesota Oncology Hematology, P.A., Minneapolis
RecruitingPhase 2/3
Ages 18 and older · Women · Updated May 2, 2024 · NCT05797831From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.